Analysts Issue Forecasts for C4 Therapeutics FY2029 Earnings

C4 Therapeutics, Inc. (NASDAQ:CCCC) – Equities research analysts at Brookline Capital Management issued their FY2029 earnings per share (EPS) estimates for shares of C4 Therapeutics in a report released on Monday, January 6th. Brookline Capital Management analyst L. Cann expects that the company will post earnings of $28.08 per share for the year. The consensus estimate for C4 Therapeutics’ current full-year earnings is ($1.52) per share.

Other research analysts have also recently issued reports about the stock. Stephens assumed coverage on shares of C4 Therapeutics in a research note on Monday, November 18th. They set an “equal weight” rating and a $4.00 price objective for the company. Wells Fargo & Company raised C4 Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $8.00 to $12.00 in a report on Thursday, December 19th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, C4 Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $10.67.

C4 Therapeutics Trading Down 5.6 %

NASDAQ:CCCC opened at $3.86 on Wednesday. The company has a market capitalization of $272.47 million, a P/E ratio of -2.27 and a beta of 2.96. The firm has a 50-day moving average price of $4.48 and a two-hundred day moving average price of $5.39. C4 Therapeutics has a twelve month low of $3.43 and a twelve month high of $11.88.

C4 Therapeutics (NASDAQ:CCCC) last posted its earnings results on Thursday, October 31st. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.05. The company had revenue of $15.36 million for the quarter, compared to analyst estimates of $5.95 million. C4 Therapeutics had a negative return on equity of 42.45% and a negative net margin of 313.35%.

Institutional Investors Weigh In On C4 Therapeutics

Several hedge funds have recently made changes to their positions in the business. Point72 DIFC Ltd purchased a new position in C4 Therapeutics during the third quarter worth about $51,000. Headlands Technologies LLC purchased a new position in shares of C4 Therapeutics during the 2nd quarter worth about $45,000. Cynosure Group LLC purchased a new position in shares of C4 Therapeutics during the 3rd quarter worth about $57,000. B. Riley Wealth Advisors Inc. acquired a new stake in shares of C4 Therapeutics in the second quarter worth approximately $51,000. Finally, Aigen Investment Management LP acquired a new position in C4 Therapeutics during the third quarter worth approximately $82,000. Institutional investors and hedge funds own 78.81% of the company’s stock.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.